Ebola virus disease: facts and fears by Karimi, A.
International Journal of Epidemiologic Research, 2015; 2(1): 1-3.
*Corresponding author: Dr. Ali Karimi, Medical Plants Research Center, Shahrekord University of
Medical Sciences, Shahrekord, IR. Iran. Tel: 00983833346692; E-mail: kakarimi63@yahoo.com
1
ijer.skums.ac.ir
Ebola virus (EBOV) is an enveloped
virus including a negative single strand
genome in its virion with cylindrical/tubular
morphology. EBOV is the causative agent of
Ebola virus disease (EVD), which is also
involved in the outbreak observed in Central
Africa since 1976. EVD is a complex
zoonotic viral disease which is highly
virulent in human. The transmission of
Ebola infection is not usually high. In
addition, the initial human-to-human
transmission of EBV occurs via contact with
the fluids of infected patients. Since there is
no available established treatment or vaccine
for Ebola, symptomatic therapy and strict
quarantine seems to be adequate for
preventing its transmission. This virus is not
airborne, foodborne or waterborne. Due to
the fear from EVD and the potential
outbreak at any given moment, this article
discusses the main epidemiological
characteristics of the disease.
The only member of Ebola virus species
is EBOV, which is the most dangerous virus
among the five known viruses within the
genus EBOV.1,2 EBOV is an enveloped
virus which has a negative single strand
genome in its virion with cylindrical/tubular
morphology. Virological investigations have
identified the EBOV (formerly Zaire
EBOV) as the causative agent of EVD,
which was also involved in the outbreak
observed in Central Africa since 1976.3,4 In
fact, EVD is a complex zoonotic viral
disease that is highly virulent in human.5
The disease had previously been referred to
as “Ebola hemorrhagic fever” because some
Ebola patients did not present hemorrhage.
Human has been fighting against the
EVD since its first known outbreak in 1976
in southern Sudan and Yambuku,
Democratic Republic of Congo (DRC) near
the Ebola River. The first known person
infected with Ebola was a 44-year-old man
in northern DRC, on 26 August 1976, with
symptoms beginning with a high fever of
39.2°C and hemorrhage and then he died
from severe hemorrhage. In the following
months, till late October, there was an
outbreak of Ebola, with 280 deaths among
318 patients.6 According to the data from the
World Health Organization, after the first
outbreak in 1976 (with 431 deaths), the
disease appeared in Sudan three years later
and then disappeared for 15 years. Later, a
large outbreak appeared in 1995 in DRC
with 250 deaths, 2001-2002 in Uganda with
224 deaths, and 2002-2003 and 2007 in
Congo with respectively 128 and 187
deaths. In fact, during the past 40 years, the
EVD disappeared after an outbreak in one
region and then erupted in another with no
warning.4
The largest recorded outbreak of EVD
was striking in West Africa, apart from its
previously reported outbreaks since
December 2013.3 The current Ebola
epidemic is unique from the first outbreak in
West Africa, as it is different from the
pattern of outbreaks typically observed in
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Central Africa. Beginning in Guinea in
December 2013, the present outbreak was
spread to Sierra Leone, Liberia, and Nigeria,
and is now the largest outbreak in its history.
The first case in Guinea was a 2-year-old
boy who died six days after presenting
typical symptoms of Ebola infection.4 Since
then, a great attention has been paid by
media to the current Ebola epidemic across
the world. As a result, the question is
whether the disease, which is generally
limited to Africa, may cause an outbreak in
other parts around the world at any given
moment.
Although there are currently no clear
indicators of the source of infection, fruit
bats of the Pteropodidae family has been
considered as the natural host of the EBOV,
which is also thought to be transmitted by
monkeys, gorillas, and chimpanzees. During
the current outbreak, a rapid accumulation
of inter- and intra-host genetic variation was
observed in sequencing of EBOV genome
from 78 patients with EBOV in Sierra
Leone, which allowed us to characterize the
patterns of viral transmission within the first
weeks of the epidemic. West African variant
has been already demonstrated to likely
diverge from central African around 2004
and then transmitted from Guinea to Sierra
Leone in May 2014, with a sustained
human-to-human transmission subsequently,
with no additional zoonotic evidence.7 Thus,
in the current outbreak, which has caused high
mortality, person-to-person transmission via
infected body fluids has been suggested to
be the only mode of the spread.8
Additionally, the data (1976-2014) indicated
that EVD is a zoonotic disease with
infection in bats and primates and potential
transmission to human. Using species
distribution models, however, indicated a
very low probability of transmission to
human.5
Furthermore, based on some
epidemiological studies, the transmission of
Ebola infection was not likely high. For
example, in a study on the outbreaks in DRC
(1995) and Uganda (2000), the basic
reproductive number (i.e., the average
number of secondary infections generated
by one primary case in an entirely
susceptible population or secondary attack
rate) of Ebola was estimated 2.7,9 ranging
from 1.34 to 3.65.10, 11 However, if the
necessary interventions are performed, the
effective reproduction number may
dramatically decrease to 0.3-0.4. This
reduction would be possible, because the
transmission occurs mainly in hospitals and
funerals, where it can be easily controlled.9
Moreover, if the reproductive number is less
than one, then a patient with the disease
cannot transmit the disease to another person
during the infection period.
In addition, the initial human-to-human
transmission of EBV has been demonstrated
to occur via contact with the fluids of an
infected patients, even though this virus is
not airborne, foodborne or waterborne.
Furthermore, the EBOV could not infect
another individuals during the incubation
period (i.e., the period between the initial
infection and the onset of symptoms), which
can be 2-21 days (generally 8-9 days) for the
EBOV. As a result, if a person with history
of contact with an Ebola patient, or a patient
suspected to have current Ebola fever, then
immediate actions such as quarantine,
treatment and management by the hospital
can affect on the spread of the outbreak.
However, even after recovery, the virus may
still be found in the body fluids of the
patient for an extended period. In another
study, the EBOV was detected inside the
semen of the patients three months after
recovery.12 Thus, it is important to know if
the patient could be released from isolation
just after confirming that the EBOV has no
longer remained.
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By increasing population and
international connectivity through airlines
since the first detection of EVD in 1976, the
dynamics of human-to-human secondary
transmission in contemporary outbreaks
would be very different compared to those
of the past.5 The pandemics of Ebola could
show an obvious independency from any
season. Generally, human is susceptible to
the EBOV irrespective of gender or age.
Finally, it is noteworthy that although there
is currently no established treatment or
vaccine.13-15 For EBOV worldwide,
symptomatic therapy and strict quarantine
are the potential and adequate preventive
strategies of its transmission. Proper risk
communication and understanding Ebola
would be the most important step to avoid
the unnecessary anxiety and fear in the
community.8, 12
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